AVEO Pharmaceuticals (AVEO)

12.60 +0.41  +3.36%  May 25, 11:00PM Go Pro
Watch this stock
View Full Chart AVEO Price Chart

Key Stats

Market Cap 544.95M
Revenue Growth -99.36%
Profit Margin -3866%
Earnings Yield -18.33%
Dividend Yield 0.00%
Earnings Per Share TTM -2.31
PE Ratio
Price / Sales Ratio 16.98
52 Week High 21.55
52 Week Low 10.40
Beta
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 23 AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors Street Insider
May 17 Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold Others In ...
May 17 $AVEO is -5.2% down since open on unusual high volume and -6.4% down since close. by TradeBot
May 17 From EArlier: AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority St...
May 16 RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp by russe9
May 16 ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj by justfurkids
May 16 Drug Fails: At Least It's Approved Already Fool
May 16 AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozan...
May 16 ASCO '12 Abstract Dump: Cancer Stocks in Focus
May 10 Aveo Pharmaceuticals inked deal for new HQ
May 10 $AVEO http://stks.co/3lp8 from watch list and up to first resistance line on volume of 85% full day average by StockTiger
May 10 tried to get $AVEO but its too thin and can't get a fill anywhere by jmaula

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Biotechnology

AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is based in Cambridge, Massachusetts.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AVEO Pharmaceuticals is down 31.37% over the last year vs S&P 500 Total Return up 1.62%, ONYX Pharmaceuticals up 9.68%, and Exelixis down 59.28%.

  • AVEO Total Returns
  • ^SPXTR Total Returns
  • ONXX Total Returns
  • EXEL Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring AVEO

Did AVEO Pharmaceuticals make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

AVEO Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
AVEO 12.60 +0.41 +3.36% 544.95M
AVD 25.75 -0.01 -0.04% 710.96M
AVCA 6.199 +0.26 +4.36% 36.08M
AVB 139.84 -1.30 -0.92% 13.31B
AVAV 21.53 -0.11 -0.51% 475.81M
AVA 25.45 -0.04 -0.16% 1.490B
BAMM 3.24 +0.02 +0.62% 51.22M
BAM 31.76 +0.16 +0.51% 19.77B
BALT 3.80 -0.07 -1.81% 64.60M
BAK 11.30 +0.15 +1.35% 2.552B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close